What is NovaBridge Biosciences's earnings per share (EPS)?

NovaBridge Biosciences (NBP) reported diluted earnings per share of $-0.21 for fiscal year 2025. This represents a -75.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

NovaBridge Biosciences Financials

NBP

Source SEC Filings (10-K/10-Q) Data as of Dec 31, 2025 Currency USD FYE December

This page shows NovaBridge Biosciences (NBP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NBP FY2025 2026-06-16

NovaBridge’s cash runway is being rebuilt through share issuance while operating burn stays unusually asset-light.

Over the last two valid years, free cash burn collapsed from -$184.0M to -$20.6M, even as R&D spending moved higher. In the latest year, net loss was -$46.3M but operating cash outflow was only -$20.6M, which means accounting loss and cash consumption have decoupled rather than worsening together.

The balance sheet was reloaded with cash: year-end cash reached $210.6M while total liabilities stayed modest at $29.6M. That rebuild came alongside shares outstanding rising to 265.4M from 187.5M, pointing to equity financing as the main source of runway rather than borrowing.

This remains a cash-burn story driven by operations, not capital equipment: capital spending was only $7K, so free cash flow stayed almost identical to operating cash flow. That makes the business structurally asset-light, with funding needs tied mainly to research and staffing decisions rather than to maintaining a heavy physical footprint.

Financial Health Signals

Financial health score pending refresh

We are recalculating NovaBridge Biosciences's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

NovaBridge Biosciences passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.45x

For every $1 of reported earnings, NovaBridge Biosciences generates $0.45 in operating cash flow (-$20.6M OCF vs -$46.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$94.2M

YoY-84.3%

NovaBridge Biosciences's EBITDA was -$94.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 84.3% from the prior year.

Net Income

-$46.3M

YoY-108.1%

NovaBridge Biosciences reported -$46.3M in net income in fiscal year 2025. This represents a decrease of 108.1% from the prior year.

EPS (Diluted)

$-0.21

YoY-75.0%

NovaBridge Biosciences earned $-0.21 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 75.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$20.6M

YoY+60.9%

NovaBridge Biosciences generated -$20.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 60.9% from the prior year.

Cash & Debt

$210.6M

YoY+208.6%

5Y CAGR-22.0%

NovaBridge Biosciences held $210.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

265M

YoY+41.6%

5Y CAGR+10.0%

NovaBridge Biosciences had 265M shares outstanding in fiscal year 2025. This represents an increase of 41.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-20.0%

YoY-9.0pp

5Y CAGR-28.4pp

NovaBridge Biosciences's ROE was -20.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 9.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$62.9M

YoY+189.0%

5Y CAGR-16.1%

NovaBridge Biosciences invested $62.9M in research and development in fiscal year 2025. This represents an increase of 189.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$7K

YoY-85.4%

5Y CAGR-64.4%

NovaBridge Biosciences invested $7K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 85.4% from the prior year.

NBP Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	$632K	N/A	$13.8M-94.2%	$236.4M
Cost of Revenue	N/A	N/A	N/A	$3.9M-45.8%	$7.3M	N/A
Gross Profit	N/A	N/A	N/A	-$5.5M-184.3%	$6.5M	N/A
R&D Expenses	$62.9M+189.0%	$21.8M+1.5%	$21.4M-4.9%	$22.5M-88.2%	$190.3M+26.1%	$150.9M
SG&A Expenses	$31.4M+5.8%	$29.7M+5.3%	$28.2M-2.8%	$29.0M-79.5%	$141.2M+129.0%	$61.7M
Operating Income	-$94.3M-83.3%	-$51.4M+28.6%	-$72.0M-35.7%	-$53.1M	N/A	N/A
Interest Expense	N/A	N/A	$102K+10100.0%	$1K	$0-100.0%	$147K
Income Tax	$0	$0	$0-100.0%	$103K+120.8%	-$495K-126.4%	$1.9M
Net Income	-$46.3M-108.1%	-$22.2M+89.3%	-$207.7M+44.0%	-$371.1M-1.4%	-$365.9M-607.0%	$72.2M
EPS (Diluted)	$-0.21-75.0%	$-0.12+89.0%	$-1.09+44.4%	$-1.96+6.2%	$-2.09-554.3%	$0.46

Metric	Q4'25	Q3'25	Q2'25	Q4'24	Q3'24	Q4'23	Q4'22	Q2'22
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NBP Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$260.5M+22.5%	$212.7M-42.4%	$368.9M-37.5%	$590.6M-32.8%	$878.9M-9.5%	$970.7M
Current Assets	$217.5M+23.1%	$176.7M-46.4%	$329.9M-37.3%	$525.8M-29.9%	$750.4M-8.4%	$819.0M
Cash & Equivalents	$210.6M+208.6%	$68.3M-76.6%	$291.5M-15.0%	$342.9M-38.0%	$552.9M-24.2%	$729.3M
Inventory	N/A	N/A	N/A	$0-100.0%	$4.3M	N/A
Accounts Receivable	N/A	N/A	N/A	$0-100.0%	$5.2M-74.0%	$20.0M
Goodwill	N/A	N/A	N/A	$23.6M-7.6%	$25.5M+2.4%	$24.9M
Total Liabilities	$29.6M+156.8%	$11.5M-90.9%	$126.3M-25.1%	$168.7M+3.2%	$163.5M+50.9%	$108.3M
Current Liabilities	$26.9M+218.1%	$8.5M-85.5%	$58.1M-47.1%	$109.9M+12.3%	$97.9M+10.9%	$88.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$230.9M+14.8%	$201.2M-17.1%	$242.6M-41.9%	$417.8M-41.6%	$715.1M-17.1%	$862.4M
Retained Earnings	-$1.3B-3.6%	-$1.3B-1.8%	-$1.3B-27.0%	-$994.9M-45.6%	-$683.4M-120.4%	-$310.1M

Metric	Q4'25	Q3'25	Q2'25	Q4'24	Q3'24	Q4'23	Q4'22	Q2'22
Total Assets	$260.5M-6.1%	$277.4M+34.2%	$206.7M-2.8%	$212.7M	N/A	$368.9M-37.5%	$590.6M-20.7%	$745.2M
Current Assets	$217.5M-6.6%	$232.8M+38.9%	$167.6M-5.1%	$176.7M	N/A	$329.9M-37.3%	$525.8M-18.4%	$644.2M
Cash & Equivalents	$210.6M-7.6%	$228.1M+37.9%	$165.4M+142.3%	$68.3M-13.9%	$79.3M-72.8%	$291.5M-15.0%	$342.9M-38.1%	$554.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$76K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	$23.6M-2.9%	$24.3M
Total Liabilities	$29.6M+59.9%	$18.5M+85.4%	$10.0M-13.4%	$11.5M	N/A	$126.3M-25.1%	$168.7M+15.9%	$145.6M
Current Liabilities	$26.9M+67.1%	$16.1M+119.0%	$7.3M-13.1%	$8.5M	N/A	$58.1M-47.1%	$109.9M+24.8%	$88.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$230.9M-10.8%	$258.9M+31.6%	$196.7M-2.2%	$201.2M-8.5%	$219.7M-9.4%	$242.6M-41.9%	$417.8M-30.3%	$599.6M
Retained Earnings	-$1.3B-2.4%	-$1.3B-0.5%	-$1.3B-0.7%	-$1.3B	N/A	-$1.3B-27.0%	-$994.9M-23.4%	-$806.5M

NBP Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$20.6M+60.9%	-$52.7M+71.3%	-$183.8M-15.0%	-$159.9M-4.7%	-$152.7M-329.8%	$66.4M
Capital Expenditures	$7K-85.4%	$48K-70.7%	$164K-92.2%	$2.1M-55.5%	$4.7M+282.8%	$1.2M
Free Cash Flow	-$20.6M+60.9%	-$52.7M+71.3%	-$184.0M-13.6%	-$162.0M-2.9%	-$157.4M-341.3%	$65.2M
Investing Cash Flow	N/A	N/A	$14.4M-78.3%	$66.5M+158.2%	-$114.1M-268.8%	-$30.9M
Financing Cash Flow	N/A	N/A	$1.1M-82.6%	$6.1M-93.4%	$93.2M-82.3%	$527.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$335K-96.1%	$8.6M+187.6%	$3.0M	$0-100.0%	$5.3M

Metric	Q4'25	Q3'25	Q2'25	Q4'24	Q3'24	Q4'23	Q4'22	Q2'22
Operating Cash Flow	-$14.6M-893.7%	$1.8M	N/A	-$10.9M-230.0%	$8.4M	N/A	N/A	N/A
Capital Expenditures	$0	$0	N/A	$38K+3700.0%	$1K	N/A	N/A	N/A
Free Cash Flow	-$14.6M-893.7%	$1.8M	N/A	-$11.0M-230.5%	$8.4M	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$0	$0	N/A	N/A	N/A

NBP Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	47.3%	N/A
Operating Margin	N/A	N/A	-11395.1%	N/A	N/A	N/A
Net Margin	N/A	N/A	-32868.5%	N/A	-2648.7%-2679.3pp	30.5%
Return on Equity	-20.0%-9.0pp	-11.1%+74.6pp	-85.6%+3.2pp	-88.8%-37.6pp	-51.2%-59.5pp	8.4%
Return on Assets	-17.8%-7.3pp	-10.4%+45.9pp	-56.3%+6.5pp	-62.8%-21.2pp	-41.6%-49.1pp	7.4%
Current Ratio	8.09-12.8	20.90+15.2	5.67+0.9	4.78-2.9	7.66-1.6	9.28
Debt-to-Equity	0.13+0.1	0.06-0.5	0.52+0.1	0.40+0.2	0.23+0.1	0.13
FCF Margin	N/A	N/A	-29107.9%	N/A	-1139.5%-1167.1pp	27.6%

Metric	Q4'25	Q3'25	Q2'25	Q4'24	Q3'24	Q4'23	Q4'22	Q2'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	8.09-6.4	14.47-8.4	22.82+1.9	20.90	N/A	5.67+0.9	4.78-2.5	7.31
Debt-to-Equity	0.13+0.1	0.07+0.0	0.050.0	0.06	N/A	0.52+0.1	0.40+0.2	0.24
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

Is NovaBridge Biosciences profitable?

No, NovaBridge Biosciences (NBP) reported a net income of -$46.3M in fiscal year 2025.

What is NovaBridge Biosciences's EBITDA?

NovaBridge Biosciences (NBP) had EBITDA of -$94.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is NovaBridge Biosciences's return on equity (ROE)?

NovaBridge Biosciences (NBP) has a return on equity of -20.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is NovaBridge Biosciences's free cash flow?

NovaBridge Biosciences (NBP) generated -$20.6M in free cash flow during fiscal year 2025. This represents a 60.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is NovaBridge Biosciences's operating cash flow?

NovaBridge Biosciences (NBP) generated -$20.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are NovaBridge Biosciences's total assets?

NovaBridge Biosciences (NBP) had $260.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are NovaBridge Biosciences's capital expenditures?

NovaBridge Biosciences (NBP) invested $7K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does NovaBridge Biosciences spend on research and development?

NovaBridge Biosciences (NBP) invested $62.9M in research and development during fiscal year 2025.

How many shares does NovaBridge Biosciences have outstanding?

NovaBridge Biosciences (NBP) had 265M shares outstanding as of fiscal year 2025.

What is NovaBridge Biosciences's current ratio?

NovaBridge Biosciences (NBP) had a current ratio of 8.09 as of fiscal year 2025, which is generally considered healthy.

What is NovaBridge Biosciences's debt-to-equity ratio?

NovaBridge Biosciences (NBP) had a debt-to-equity ratio of 0.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is NovaBridge Biosciences's return on assets (ROA)?

NovaBridge Biosciences (NBP) had a return on assets of -17.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is NovaBridge Biosciences's cash runway?

Based on fiscal year 2025 data, NovaBridge Biosciences (NBP) had $210.6M in cash against an annual operating cash burn of $20.6M. This gives an estimated cash runway of approximately 123 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is NovaBridge Biosciences's Piotroski F-Score?

NovaBridge Biosciences (NBP) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are NovaBridge Biosciences's earnings high quality?

NovaBridge Biosciences (NBP) has an earnings quality ratio of 0.45x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.